Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Medicine for Membranous Nephropathy
2018-002476-40Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of rituximab in idiopathic membranous glomerulonephritis (IMG) and membranous glomerulonephritis (MGN) (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Clinical remission at month 12. Started Aug 2018; status: completed.
02
Drugs
rituximab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on 2018-002476-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002476-40.